The rise of Sildenafil initially fueled a surge for major pharmaceutical companies, however recent changes present a uncertain scenario for shareholders. Generic competitors are reducing profits, and continued https://iwandreg268793.blue-blogs.com/49370066/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment